Next Phase Newsletter

The firm is a publicly traded company focused on oncology therapeutics. The firm is seeking therapeutic opportunities in the oncology space. The pharma is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies.

The pharma is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies.

The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The pharma is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

The venture fund is an early stage investor in emerging life science technologies that was founded in 2003 and is based in Seattle, WA, with additional offices in New York City and San Diego. The firm closed its fourth fund in 2015 at $62.8 million. The firm seeks to invest in promising early-stage assets, create a company around each asset and then directly manage the startup. The firm’s investment sizes vary from $1-40 million. Investments are made at the seed stage or in Series A venture rounds; the firm prefers to be the first institutional investor. The firm has invested in assets sourced throughout the USA and has evaluated investment opportunities globally.

The firm primarily invests in therapeutics-focused opportunities. The firm is technologically agnostic and is open to any indication area, with a particular interest in CNS, digital health, oncology and immunology. The firm is interested in preclinical-stage assets and will consider investing in assets as early as the discovery stage.

The firm is open to working with both academic projects and entrepreneurs, and also deprioritized pharma assets. The firm generally does not make new investments into companies any later than the Series A stage. The firm supplies management and technical expertise to develop an asset if the company does not have a full management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A Boston area-based venture firm specializes in early stage opportunities in med-tech, diagnostics, and instruments. Currently, the firm has a total AUM of $125 million. Typically, the firm initially invests in a start-up at the early stage, but reserves capital for participation later on. The firm typically makes a first investment in the range of $1-3 million, but is open to making larger or smaller allocations as opportunities arise. The firm expects to invest a total in the range of $7-12 million in a given portfolio company as it makes progress toward a successful exit. The firm prefers to act as a lead investor for early stage deals.

The firm is most interested in companies developing medical devices, diagnostics tools and instrumentation. The firm is looking for companies targeting global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. The firm is willing to invest in companies that are pre-prototype as well as those that have a working prototype of their product.

The firm looks to act as a long term strategic partner with its portfolio companies. The firm looks for experienced management teams and generally looks to take a board seat into companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A registered investment consultancy firm is involved with independent advisory, outsourced CIO, and direct investments. The firm acts as the consultant role to advise global family offices with their investment objectives. The firm is looking for investment leads in early-stage life science industry. Companies who are looking to raise their series B – series C rounds would be in their sweet spot. The firm typically invests in $1M-25M, which depends on the stage of development.

The firm is also open to looking at earlier stage companies but the investment size might vary. The firm is looking for companies in the US (60%), China (20%), UK, Germany, India, and other countries with emerging life science technologies.

The firm is opportunistic in sectors and is willing to consider any indications.

The firm has no specific requirements for companies. The firm might take an observer seat or board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A PE firm based in China manages 2 active funds – the RMB and USD Funds – that focus on investments in the life science space. The RMB Fund invests $5-40 M in companies based in China, and the USD Fund invests $5-10 M in companies of all parts of the world, with a focus in US and China. With these funds, the firm will make 1-2 investments per year in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.

The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and digital health. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond, but may consider companies with pre-clinical or early clinical assets if they demonstrate high potential. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.

The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office behind a large industrial engineering firm invests in and incubates new technologies in the medical device and consumer health sectors. The firm is invests directly into early stage companies, focusing on opportunities in which the firm’s engineering and commercialization expertise can provide a value-add. The firm’s investments may include equity financing, services such as prototyping and design, and other structures such as royalties. The firm invests worldwide.

The firm focuses on medical technology and consumer health, including devices, diagnostics, sterilization, blood testing, sensors, MRI/Radiation machines, and home health products. The firm is a multi-stage investor, and has worked with entrepreneurs as early as idea-stage. The firm invests in all classes of medical device including PMA opportunities. Hardware only.  No pure software, biotech/drugs/medication or services businesses.

The firm is focused on investing in companies in which the firm’s expertise is a relevant value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm linked to a large provider of preventative and diagnostic services currently has a $50M seed stage fund through which they invest mainly in Seed to Series A companies across all geographies. Despite the fund’s affiliation with this large company, the firms are separate entities and as an institutional venture capital firm, financial return is an important factor. However, because of this affiliation, the firm is able to leverage corporate benefits to support the growing needs of their portfolio companies. As of March 2021, the firm has invested in 6 EMEA companies and 8 USA companies. Initial sizes of investment can largely vary, from $250K to 4M and a portion of the fund is reserved for follow-on investment.

Traditionally, the firm has been most interested in healthcare IT and services companies that address important problems in the healthcare industry, including reducing healthcare costs and improving patient outcomes. However, the firm has been pushing beyond healthtech and pursuing investments in the fields of diagnostics, genomics, and medtech. The firm is not interested in biotech.

The firm is able to leverage their relationship with its parent company to provide hands-on support for their portfolio companies. The firm is open to both leading and co-investing and has done both. The firm is more likely to lead and seek board representation for companies that are based in proximity with the firm’s team. The firm does not have specific requirements for the company or management team as long as they have compelling technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.